Summary To establish whether loss of heterozygosity (LOH) for chromosome 16q in Wilms' tumours confers an adverse prognosis, DNA from 40 Wilms' tumour/normal pairs were analysed using highly polymorphic microsatellite markers along the length of 1 6q. Fifteen per cent of tumours showed LOH for 16q. Although the common region of allele loss spanned the 16q24-qter region, a second distinct region of LOH was identified in 16q21. (Coppes et al. 1992 : Maw et al. 1992 : Grundy et al. 1994: Austruy et al. 1995 : Redeker et al 1996 . Using a panel of informative markers for the region 16ql2.2-qter. Maw et al (1992) were the first to demonstrate LOH for 16q in 9 (20%c) of 45 informatiVe patients by Southem blot analysis. A larger follow--on study. as part of NWTS4. involving 232 patients. found a similar frequency of LOH at 17%7. but used only polymorphic markers that mapped to the distal 16q22-qter region (Grundv et al. 1994). In the study by Coppes et al (1992). using only two polymorphic markers mapping to 16q22.2 and 16q24.3. LOH was identified in 20% of tumours. The most recent studv. albeit in a relatively small group of patients (Austruy et al. 1995). found the highest level of LOH (25%7c) using a large panel of restriction length polymorphisms and microsatellite probes. Furthermore. LOH for 16q has been associated with a worse outcome because these patients have a relapse rate 3.3 times higher than those with tumours retaining heterozygosity for 16q (Grundy et al 1994).
The overall cure rate for Wilms' tumour is nowv 85%7c. a consequence of consistent improvement in treatment strategies (D'Ancio et al. 1989 : Pritchard et al. 1995 (D'Angio et al. 1981 ). The addition of doxorubicin to vincristine and actinomycin D in the National Wilms' Tumour Study (NWTS-3) improxed the relapse-free sun-ival bv 10%c and the overall survival by 5% in patients with favourable histology' stage 3 disease (D'Angio et al. 1989) . In other words. among children w ith stagye 3 disease. there is a subset of patients that benefit from the addition of doxorubicin. although the majority may still be cured w-ithout using this drug. This improvement in sunrival is. however. achieved at a price. as the use of doxorubicin is associated with considerable cardiac late effects (Goonrn et al. 1990 : Sorenson et al. 1995 . Clearly. if we are to continue to improve the outcome of patients with Wilms' tumour. Vihile minimizincr the late effects of curative therapy. new prognostic factors are required.
Cytogenetic abnormalities of chromosome 16 has-e been reported in 30%7 of Wilms' tumour and predominantly involve the long arm (Slater et al. 1992 : Austruy et al. 1995 . Two regions of interest have been identified from these studies. a proximal locus at 16q 1-13 and a more distal region involving 16q2l-24-qter (Slater et al. 1992 ). An identical translocation. der (16)t(l:16)(q21:ql3). has also been reported in four Wilms' tumours (Solis et al. 1988 : Wan--Wuu et al. 1990 . and a der (16)t(l:16)(ql2:ql2) was reported by Kaneko et al (1991) .
Tumour-specific allelic loss has been thought to represent the second hit. resulting in the inactiN-ation of a tumour-suppressor gene and can be detected by LOH analysis (Knudson and Strongy. 1972: Cavenee et al. 1983 ). Molecular studies have found LOH for polymorphic markers on 16q in 10-25%7 of Wilms' tumours (Coppes et al. 1992 : Maw et al. 1992 : Grundy et al. 1994 : Austruy et al. 1995 : Redeker et al 1996 . Using a panel of informative markers for the region 16ql2.2-qter. Maw et al (1992) were the first to demonstrate LOH for 16q in 9 (20%c) of 45 informatiVe patients by Southem blot analysis. A larger follow--on study. as part of NWTS4. involving 232 patients. found a similar frequency of LOH at 17%7. but used only polymorphic markers that mapped to the distal 16q22-qter region (Grundv et al. 1994 ). In the study by Coppes et al (1992) . using only two polymorphic markers mapping to 16q22.2 and 16q24.3. LOH was identified in 20% of tumours. The most recent studv. albeit in a relatively small group of patients (Austruy et al. 1995) . found the highest level of LOH (25%7c) using a large panel of restriction length polymorphisms and microsatellite probes. Furthermore. LOH for 16q has been associated with a worse outcome because these patients have a relapse rate 3.3 times higher than those with tumours retaining heterozygosity for 16q (Grundy et al 1994) .
Because cytogenetic and molecular studies of Wilms' tumours clearly suggest a role for grenes on 16q in the molecular pathology of this tumour. we have undertaken LOH analysis for 16q markers using a large. well-characterized series of sporadic Wilms' tumours. Our results clearly show that LOH is relatively frequent in Wilms' tumours. especially in patients with an adverse outcome.
MATERIALS AND METHODS
DNA was prepared from tumour tissue and lymphocNies using standard phenol-chloroform extraction procedures described by Wadey et al (1990) . The optimal polymerase chain reaction (PCR) conditions denatured at 950C for 3 min. An aliquot of 3 j1 of the resultant solution was loaded onto a 6% denaturing polyacylamide gel. The gel was run at 60 W constant power in 1 x Tns actate EDTA buffer, the lengti of time depended on the fiagnt size. Gels were then fixed in 10% methaVo10% acetic add before drying and exposure to XAR-5 film (Kodak) for 12-72 h without an intensifying screen.
Tumour samples were collected between May 1983 and May 1990. All patients referred to the Hospital for Sick Children, Great Ormond Street. with a histopathological diagnosis of Wilms' tumour were treated on sequential United Kingdom Children's Cancer Study Group protocols UKWI and UKW2 (Pritchard et al, 1995; CD Mitchell, personnal communication) . All children received uniform treatment as per the protocol and have been followed up for at least 7 years. heterozygous at three or more of the ten polymorphic loci tested.
RESULTS
The physical location of the polymorphic microsatellite markers was obtained from Kozman et al (1995) and Doggett et al (1995) and from the Genome database (Gyapay et aL 1994) .
Clinikoathological details of the tumours
Of the 40 patients analysed in this study. 13 had stage 1 disease. two stage 2, 13 stage 3. seven stage 4 and five had bilateral disease. Thirty-eight patients had 'favourable' histology (FH) tumours and two had 'unfavourable' histological features (UH). Five children relapsed and three of these patients died of disease. with two being cured by second-line therapy.
Loss of heerozygosity on chromosome 16
Constitutional and tumour DNA from 40 patients were used to investigate the frequency of LOH along the long arm of chromosome 16. using seven polymorphic microsatellite markers (D16S413, D16S 520, D16S 518, D16S 512, D16S 514. D16S 419 and D16S519). The physical location of the polymorphic microsatellite markers is shown in Table 1 and was determined from the genome database and current literature (Gyapay et al 1994; Doggett et al 1996) . All polymorphic microsatellite markers had a heterozygosity frequency above 0.75 (see Table 1 ).
Six ( thereby defining a second distinct region that potentially contains a tumour-supressor gene(s) (Figure 2) . The most proximal marker tested was D16S519. which mapped to 16pl2. This marker was informative in all tumours except GOS198 and. in all of the tumours. both alleles were retained (Figure 1 ). Thus. from the summary shown in Figure 2 . two regions of distinct LOH can clearly be identified.
Clinical outcome and LOH for 16q
Three of the 40 patients with Wilms' tumour in this series. GOS 198. 407 and 542. died of disease and the tumours from two of these. GOS 198 and 542. showed LOH for markers on 16q. Two other patients. GOS 101 and 358. relapsed but were cured by second-line therapy (see Table 2 ). One of these recurrent tumours. GOS101. also showed LOH for 16q. Although this tumour was stage 1 by clinicopathological staging. it had unfavourable histological features. GOS 407 was a stage 3 tumour with unfavourable histological features and this patient died I month after relapse.
There was no evidence for LOH for 16q markers in this tumour.
Overall, therefore, two of the three patients who died of the disease had LOH for 16q. The only patient with stage 1 disease, who relapsed. also showed LOH for this region ( Maw et al (1992) provided molecular evidence for the existence of two discrete regions of LOH on 16q. Region 16ql3 was implicated by the discovery of an interstitial deletion between 16q13 and 16q21 in a single tumour. A second tumour had an interstitial deletion. but the extent of the deletion could not be defined because not all of the probes that were used between 16q11.2 and q21 were informative. In five other tumours in this study, LOH was restricted to the 16q22-qter region (Maw et al. 1992) . From our analysis it was also possible to establish, unequivocally. that two distinct regions of 16q show LOH in Wilms' tumorigenesis. Clearly LOH for the 16q24-qter region was the most consistent finding but one of the six tumours showed LOH that was restricted to the 16q21 region. Tumours from several patients showing larger regions of LOH were. unfortunately.
constitutionally homozygous at critical loci. and so whether any of the other tumours in fact showed 16q2 1-specific LOH could not be determined (Maw et al, 1992) . Importantly. none of these six tumours showed LOH extending to 16q13. which means that, in combination with previous studies, the proximal site of any potential tumour-suppressor gene is restricted to 16q21. In two other studies (Grundy et al, 1994 : Coppes et al. 1992 . only polymorphic markers that mapped to the telomeric region of 16q were used and so cannot confirm the location of a putative Wi1ms' tumour (WT) gene in 16q21. Newsham et al (1995) , on the other hand. concentrated on the 16q13 region and found that 20% of their panel of 26 tumours showed LOH for the 16q13-21 region. No markers mapping distal to 16q22.1 were used in this study, however. and so it was not determined whether LOH extended all the way to 16qter. Recently, Austruy et al (1995) used a number of markers distributed along the length of 16q and identified LOH in 7/25 tumours. The region of allelic loss extended from 16qter to D16S419 in 16ql2-13. which is consistent with our study. Taken together. therefore, LOH studies for chromosome 16 in Wilms' tumour clearly define the 16q24-qter region as the most common site of allelic loss. The evidence for a tumour-supressor gene in 16q21 is still based on only a limited number of observations, which may indicate that genes in these regions are less critical in establishing the tumour phenotype. Interestingly. the der (16) t(1:16) (q21;q13) cytogenetic abnormality was noted in 10% of those tumours that could be karyotyped successfully (Matthew et al. 1996) . All of these tumours were of favourable histology and the cytogenetic abnormality did not confer an adverse prognosis (Matthew et al. 1996) . Whether the breakpoint in this tumour inactivates a critical tumour-supressor gene has not been determined, but if this is the case then loss of function of this particular gene does not lead to adverse outcome. From our studies, a clear association between LOH on 16q and higher stage/worse outcome tumours was apparent. Overall, therefore. two of the three patients who died of the disease in this series had LOH for 16q. The only patient with stage 1 disease who relapsed also showed LOH for this region. demonstrating a tendency for LOH to occur in higher stage disease or predict poor Brtsh Joumal of Cancer (1998) 78(9), 1181 -1187 0 Cancer Research Campaign 1996 prognosis in patients with stage 1 disease. Furthermore, all but one of the tumours with LOH for 16q markers were stage 3/4 or had bilateral disease at diagnosis. The remaining (sixth) tumour with LOH for 16q markers (GOS101) was stage 1 at diagnosis but had unfavourable histological features (anaplasia). This tumour recurred, but, following second-line treatments the child is alive with no detectable disease. Although the presence of anaplasia confers an adverse prognostic sign, it is stage related, and does not significantly alter the outcome of patients with stage 1 disease (D'Angio, 1989) . Given the observation of Grundy et al (1994) , who noted that LOH on 16q was associated with adverse outcome, irrespective of the stage or histological features of the tumour, it is likely that the molecular alteration in GOS 101 is more significant than the presence of anaplasia Austruy et al (1995) detected LOH for 16q markers in 7 of 25 Wilms' tumours. Two of these were considered to be stage 1 at diagnosis and in both cases the tumour recurred; one patient was subsequently cured, but the other died of disease, again supporting the hypothesis that allelic loss on 16q represents an adverse prognostic marker, irrespective of the disease stage.
Wbether the 16q locus will prove to be Wilms' tumour specific is still not clear at this time. A number of other tmo types have been found to exhibit LOH from 16q, usually in addition to a number of other chromosomal abnoralities. The region of allelic loss in a number of different tumour types also appears to involve 16q22-qter (Mugneret et al, 1988; Sato et aL 1990; Tsuda et al, 1990; Bergerheim et al, 1991; Fujimori et al, 1991; Thomas et al, 1991; Douglass et al, 1990; Dorion-Bonnet, et al 1995) , the same as that involved in Wdlms' tumour, although still a relatively large region.
Nephroblastomatosis is considered by some to be a precursor lesion for Wllms' tumour based on (a) histopathological analysis (Beckwith et al, 1990) and (b) the discovery of WTI mutations in two patients with so-called nephrogenic rests (Park et al, 1993) . LOH for markers in 16q13-qter has also been reported in one case of nephroblastomatosis (Austruy et al, 1995) . Although interesting, this observation conflicts with the hypothsis that genes on chromosome 16q are implicated in tumour progression rather than tumour initianon and, further, that the presence of LOH on 16q is associated with a poor prognosis (Grundy et al, 1994) . It should be noted that, in the kidney showing nephroblastomatosis, the tissue sampled was from the immediate vicinity of the tumour, which raises the possibility of sample contamination (Austruy et al, 1995) .
Wiedemann-Beckwith syndrome (WBS) is considered to be a Wilms' tumour predisposition syndrome (Wiedemann 1983) , and has been associated with chromosome region llpl5 by linkage studies in familial cases and the presence of cytogenetic abnormalities involving this region (Koufos et al, 1989; Ping et al, 1989; Weksberg et al, 1993) in patients with WBS. Recently, chromosome 16 has been implicated in this syndrome in two patients (Weksberg et al, 1993; Newsham et al, 1995) and in the Wllms' tumour of a patient with WBS (Austruy et al, 1995) . Both of these WBS patients had constitutional translocations derived from phenotypically normal mothers. The first (Weksberg et al, 1993) carried a t(l1;16) (pl5.5;ql2) and the second (Newsham et al, 1995) (Weksberg et al 1993; Mannens et al 1994) and, although lpl15.5 was always involved. chromosome 16 was not a consistent partner chromosome. Furthermore, of the two WBS patients with an 11; 16 translocation. one is alive with no evidence of a Wilms' tumour. the other died in the neonatal period (Weksberg et al, 1993; Newsham et al, 1995) .
There is some evidence for an association between cytogeneticdmolecular abnormalities on chromosomes 11 and 16 in Wllms' tumours. Two studies have analysed LOH in Wilms' tumours on both llp and 16q. The initial study found LOH for both chromosomes in only three of nine tumours (Maw et al, 1992) . Similar findings were reported by Coppes et al (1992) . who observed loss of chromosomal material on chromosomes 11 and 16 in three of six tumours. In our study, four of the six Wilms' tumours showing LOH on 16q had previously been analysed for LOH on chromosome 11 (Wadey et al, 1990) . Two of these four tumours showed LOH for markers on both 11 and 16. The other two tumours were not included in the LOH analysis of lIp. The fact that LOH on 16q can occur independently of LOH on lIp possibly suggest that the sequential occurrence of these two events is not required for tumorigenesis. However, LOH does not identify mutations in specific genes and so the relative contribution of genes on lIp and 16q will only be resolved when these genes have been characterized.
The association between LOH on 16q and an adverse outcome is clearly potentially very important for future clinical studies, particularly as patients entering clinical trials in the United Kingdom are randomized between immediate nephrectomy vs percutaneous biopsies before preoperative chemotherapy (C Mitchell, personal communication) . In order to evaluate LOH on 16q as a prognostic indicator, larger prospective studies involving all of the patients enrolled into the specific trials would be required. Furthermore, if the same polymorphic markers used in the current NWTS-5 trial are used to determine LOH for 16q in future studies, then the frequency of LOH for 16q will be directly comparable. Although there is increasing evidence that LOH for 16q may help stratify patients into those with biologically favourable or unfavourable disease, this possibility needs to be confirmed by analysis of larger numbers of patients. Confirmation of this relationship would possibly enable 'fine tuning' of available therapies for Wilms' tumour with the possibility of reserving the use of doxorubicin, which is cardiotoxic, for use in those patients with adverse biological and clinicopathological features. These extended studies may also serve to further narrow down the critical region of 16q.
